Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study
Maria Teresa Voso(University of Rome Tor Vergata), Simona Sica(San Antonio College), Anna Candoni(University of Udine), Giuseppe Leone(Bambino Gesù Children's Hospital), Angelo Michele Carella(San Antonio College), Alfonso Piciocchi(Fondazione Gimema Onlus), Luana Fianchi(Università Cattolica del Sacro Cuore), Arianna Masciulli(Ospedale Papa Giovanni XXIII), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Matteo Parma(Azienda Ospedaliera San Gerardo), Elisa Cerqui(San Antonio College), Carlo Finelli(Azienda USL di Bologna), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Flavia Salvi(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Francesco Spina(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonella Poloni(Marche Polytechnic University), Stella Santarone(Azienda USL di Pescara), Marianna Criscuolo(Università Cattolica del Sacro Cuore), Emilio Paolo Alessandrino, Alfredo Molteni(Istituti Ospitalieri di Cremona)
Cited by 57
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k